Anna Ractliffe
Stock Analyst at Bank of America Securities
(2.01)
# 3,261
Out of 5,073 analysts
17
Total ratings
61.5%
Success rate
1.5%
Average return
Main Sectors:
Stocks Rated by Anna Ractliffe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: FME Fresenius Medical Care AG | Reiterated: Sell | €32.00 | €38.45 | -16.78% | 11 | Oct 19, 2026 | |
| BIT: 1SXP SCHOTT Pharma AG & Co. KGaA | Upgraded: Hold | €27.00 | €24.50 | +10.20% | 1 | Oct 16, 2026 | |
| EPA: BIM bioMérieux S.A. | Upgraded: Hold | €115.00 | €86.25 | +33.33% | 1 | Dec 12, 2025 | |
| LON: RS1 RS Group plc | Upgraded: Buy | 730p | 765p | n/a | 1 | May 13, 2025 | |
| BME: FDR Fluidra, S.A. | Upgraded: Buy | €21.00 → €26.00 | €17.92 | n/a | 2 | Apr 10, 2025 | |
| AMS: LIGHT Signify N.V. | Upgraded: Buy | €29.00 | €14.21 | n/a | 1 | Nov 6, 2024 |
Fresenius Medical Care AG
Oct 19, 2026
Reiterated: Sell
Price Target: €32.00
Current: €38.45
Upside: -16.78%
SCHOTT Pharma AG & Co. KGaA
Oct 16, 2026
Upgraded: Hold
Price Target: €27.00
Current: €24.50
Upside: +10.20%
bioMérieux S.A.
Dec 12, 2025
Upgraded: Hold
Price Target: €115.00
Current: €86.25
Upside: +33.33%
RS Group plc
May 13, 2025
Upgraded: Buy
Price Target: 730p
Current: 765p
Upside: n/a
Fluidra, S.A.
Apr 10, 2025
Upgraded: Buy
Price Target: €21.00 → €26.00
Current: €17.92
Upside: n/a
Signify N.V.
Nov 6, 2024
Upgraded: Buy
Price Target: €29.00
Current: €14.21
Upside: n/a